Eton Pharmaceuticals, Inc. (ETON) is a publicly traded company in the Unknown sector. Across all available filings, 11 corporate insiders have executed 65 transactions totaling $26.1M, demonstrating a bearish sentiment with -$18.5M in net insider flow. The most recent transaction on Dec 12, 2025 involved a transaction of 6,732 shares valued at $113.3K.
No significant insider buying has been recorded for ETON in the recent period.
No significant insider selling has been recorded for ETON in the recent period.
Based on recent SEC filings, insider sentiment for ETON is bearish with an Insider Alignment Score of 15/100 and a net flow of -$18.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Eton Pharmaceuticals, Inc. (ETON) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 11 insiders are actively trading ETON stock, having executed 65 transactions in the past 90 days. The most active insider is Management Inc. Opaleye (Executive), who has made 41 transactions totaling $14.3M.
Get notified when executives and directors at ETON file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | Brynjelsen Sean | Executive | Payment | 6,732 | $16.83 | $113.3K | |
| Dec 12, 2025 | R. Gruber James | Executive | Payment | 4,542 | $16.99 | $77.2K | |
| Dec 12, 2025 | Krempa David | Executive | Payment | 6,264 | $17.00 | $106.5K | |
| Dec 12, 2025 | Erdogan-trinkaus Ipek | Executive | Payment | 85 | $16.90 | $1.4K | |
| Aug 20, 2025 | R. Gruber James | Executive | Sale | 2,631 | $16.02 | $42.1K | |
| Aug 19, 2025 | R. Gruber James | Executive | Sale | 39,082 | $16.16 | $631.6K | Large |
| Sep 11, 2024 | Inc. Opaleye Management | Executive | Purchase | 45,000 | $4.75 | $213.8K | |
| Sep 11, 2024 | Inc. Opaleye Management | Executive | Purchase | 5,000 | $4.75 | $23.8K | |
| Sep 10, 2024 | Inc. Opaleye Management | Executive | Purchase | 7,500 | $4.65 | $34.9K | |
| Sep 10, 2024 | Inc. Opaleye Management | Executive | Purchase | 50,000 | $4.65 | $232.5K | |
| Sep 22, 2022 | Brynjelsen Sean | Executive | Purchase | 10,000 | $2.10 | $21.0K | |
| Nov 17, 2021 | Inc. Opaleye Management | Executive | Sale | 25,000 | $4.67 | $116.8K | |
| Nov 16, 2021 | Inc. Opaleye Management | Executive | Sale | 11,500 | $4.86 | $55.9K | |
| Nov 16, 2021 | Inc. Opaleye Management | Executive | Sale | 938 | $4.86 | $4.6K | |
| Nov 15, 2021 | Inc. Opaleye Management | Executive | Sale | 500 | $4.80 | $2.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 38 | $22.3M | 84.5% |
Purchase(P) | 20 | $3.8M | 14.4% |
Payment(F) | 4 | $298.4K | 1.1% |
Gift(G) | 1 | $0 | 0.0% |
Conversion(C) | 2 | $0 | 0.0% |
Insider selling pressure at Eton Pharmaceuticals, Inc. has increased, with 11 insiders executing 65 transactions across all time. Total sales of $22.3M significantly outpace purchases of $3.8M, resulting in a net outflow of $18.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.